Somatostatin peptide analog
Lanreotide
Lanreotide is a somatostatin peptide analog identified in early studies as BIM 23014. It has been examined through endocrine measurements and self-assembly characterization. Supramolecular structures provide a different perspective from receptor pharmacology.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
What changed from the reference
Write the evaluated material’s complete name. A shared family organizes a search but does not establish identity or result equivalence.
- Which modification distinguishes the analog: sequence, terminus, conjugate or formulation?
- Does the study compare both entities using the same assay?
- Do the data separate molecular behavior from presentation effects?
Mechanism described in the literature
BIM 23014 was studied through GH, TSH and digestive-peptide secretion. Hormone response and physical organization of lanreotide in water are different properties requiring different methods.
Other names in the literature
- Lanreotide
- BIM 23014
A hormone panel preserves differences
The 1989 study recorded several hormones rather than GH alone. The evaluated variables did not respond uniformly under the compared conditions. Retain both changed and unchanged readouts when discussing selectivity; grouping them as general hormone regulation loses experimental information.
Nanotubes observed in water
The 2003 work characterized self-assembled lanreotide structures in water using microscopy, vibrational spectroscopy and X-ray scattering across organizational levels. Agreement among techniques supported nanotube architecture. This concerns a defined physical system; any observed aggregate is not automatically that same organization.
From molecule to organized material
Lanreotide can be studied as both a peptide entity and a self-assembled material; peptide and assembly structures are complementary descriptions. An experimental nanotube does not certify every commercial formulation's architecture. Composition, conditions and characterization must be compared, and microscopy alone cannot establish biological-response duration.
Questions and answers
Is BIM 23014 a somatostatin mixture?
No. It is the experimental designation of the analog described in the cited endocrine study.
Were nanotubes inferred from pharmacology?
No. Complementary physical techniques characterized lanreotide in water.
Sources
- Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. — J Clin Endocrinol Metab, 1989
- Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men.
- Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension. — Proc Natl Acad Sci U S A, 2003
- Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension.